CPT.F COLLPLANT BIOTECH. IS-01

Healthcare Biotechnology Frankfurt Exchange
3.50 EUR
Close of Nov 11, 2026
1.49 19.00
Market cap
EUR 10.8M
P/E
-
P/B
4.36x
ROE
-395.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is CPT.F undervalued?

Graham number

The Graham number of COLLPLANT BIOTECH. IS-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

COLLPLANT BIOTECH. IS-01 fundamental analysis

No fundamental analysis for COLLPLANT BIOTECH. IS-01 yet.

COLLPLANT BIOTECH. IS-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About COLLPLANT BIOTECH. IS-01

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a c…

Full company profile